Venus Remedies Limited (BOM:526953)
India · Delayed Price · Currency is INR 1,569.35
-81.25 (-4.92%)
At close: Jul 27, 2026
Venus Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 8,113 | 7,696 | 6,529 | 6,014 | 5,555 | 6,002 |
| 8,113 | 7,696 | 6,529 | 6,014 | 5,555 | 6,002 | |
Revenue Growth | 20.87% | 17.88% | 8.55% | 8.27% | -7.44% | 9.50% |
Cost of Revenue | 3,974 | 3,893 | 3,801 | 3,564 | 3,329 | 3,870 |
Gross Profit | 4,139 | 3,803 | 2,728 | 2,451 | 2,226 | 2,132 |
Selling, General & Admin | 2,289 | 2,149 | 1,862 | 1,697 | 1,397 | 1,281 |
Research & Development | 188.5 | 181.73 | 180.85 | 158.4 | 228.85 | 230.3 |
Other Operating Expenses | - | -23.33 | -89.82 | -5.08 | -4.86 | -4.63 |
Operating Expenses | 2,741 | 2,564 | 2,178 | 2,114 | 1,944 | 1,842 |
Operating Income | 1,398 | 1,239 | 550.12 | 336.65 | 282.13 | 290.43 |
Interest Expense | -0.3 | -0.37 | -0.65 | -0.94 | -1.18 | -3.03 |
Interest & Investment Income | - | 21.39 | 45.42 | 41.66 | 18.99 | 8.16 |
Currency Exchange Gain (Loss) | - | - | - | 59.54 | 73.24 | 64.15 |
Other Non Operating Income (Expenses) | 117.8 | 21.75 | 7.97 | 4.01 | 6.04 | 4.37 |
EBT Excluding Unusual Items | 1,516 | 1,282 | 602.85 | 440.92 | 379.22 | 364.08 |
Gain (Loss) on Sale of Investments | - | 59.37 | 16.28 | 5.51 | 0.08 | - |
Other Unusual Items | - | - | 99.13 | - | - | - |
Pretax Income | 1,516 | 1,342 | 718.27 | 446.43 | 379.3 | 364.08 |
Income Tax Expense | 354.3 | 313.64 | 265.12 | 161.53 | 113.65 | -43.16 |
Net Income | 1,162 | 1,028 | 453.15 | 284.91 | 265.66 | 407.24 |
Net Income to Common | 1,162 | 1,028 | 453.15 | 284.91 | 265.66 | 407.24 |
Net Income Growth | 116.32% | 126.83% | 59.05% | 7.25% | -34.77% | -34.07% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change | -0.20% | - | - | - | 1.30% | 6.92% |
EPS (Basic) | 86.89 | 76.90 | 33.90 | 21.31 | 19.87 | 30.86 |
EPS (Diluted) | 86.89 | 76.90 | 33.90 | 21.31 | 19.87 | 30.86 |
EPS Growth | 116.76% | 126.84% | 59.08% | 7.22% | -35.60% | -38.33% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 1,181 | 768.15 | 279.67 | 288.09 | 273.94 |
Free Cash Flow Per Share | - | 88.36 | 57.47 | 20.92 | 21.55 | 20.76 |
Dividend Per Share | - | 10.000 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 51.02% | 49.42% | 41.78% | 40.75% | 40.07% | 35.52% |
Operating Margin | 17.24% | 16.10% | 8.43% | 5.60% | 5.08% | 4.84% |
Profit Margin | 14.32% | 13.36% | 6.94% | 4.74% | 4.78% | 6.78% |
Free Cash Flow Margin | - | 15.35% | 11.77% | 4.65% | 5.19% | 4.56% |
EBITDA | 1,670 | 1,404 | 775.18 | 601.08 | 605.1 | 625.77 |
EBITDA Margin | 20.59% | 18.24% | 11.87% | 9.99% | 10.89% | 10.43% |
D&A For EBITDA | 271.88 | 164.59 | 225.06 | 264.43 | 322.98 | 335.34 |
EBIT | 1,398 | 1,239 | 550.12 | 336.65 | 282.13 | 290.43 |
EBIT Margin | 17.24% | 16.10% | 8.43% | 5.60% | 5.08% | 4.84% |
Effective Tax Rate | 23.37% | 23.38% | 36.91% | 36.18% | 29.96% | - |
Revenue as Reported | 8,231 | 7,822 | 6,688 | 6,130 | 5,658 | 6,085 |
Advertising Expenses | - | 101.9 | 104.31 | 132.54 | 84.83 | 44.26 |